ATRX Research Alliance

What ATRX Research Alliance does

ATRX Research Alliance is a 501(c)(3) nonprofit patient advocacy organization founded in 2021 and headquartered in Albuquerque, New Mexico, focused exclusively on ATR-X syndrome, an ultra-rare X-linked neurodevelopmental disorder. The organization was previously known as CureATRX and was formed through an alliance of parent-led groups to consolidate advocacy, research funding, and family support under a single entity. It is governed by a seven-person volunteer core team and serves affected families and clinicians across the United States, the United Kingdom, Canada, Japan, Argentina, and Spain/Latin America through regional sub-groups and a Facebook community of more than 900 members.

The Alliance operates a portfolio of translational research programs rather than commercial products. Its core assets and activities include a DNA biobank and patient registry built in partnership with Simons Searchlight, research biospecimens routed through Coriell, a drug repurposing initiative run with Rarebase, and gene therapy discovery work funded with the Bradbury Lab at Nationwide Children's Hospital. It is also building a Scientific Advisory Board drawn from leading ATR-X research institutions including the University of Oxford, the University of Edinburgh, the University of Ottawa, Nationwide Children's Hospital, and the Greenwood Genetic Center. The Alliance plans to convene the affected community at its inaugural Scientific and Family Conference in Columbus, Ohio in April 2026.

The business model is donation-only: the organization sells no products or services, holds no disclosed revenue figures, and operates under fiscal sponsorship from the Rare Village Foundation. Revenue is raised from individual donors and philanthropic supporters, with programs funded on a project basis through grants, family-led fundraising, and alliance contributions. As a small volunteer-led nonprofit in an ultra-rare indication, its financial scale is likely modest and its donor base relatively concentrated, though no specific financial data has been disclosed.

Name

ATRX Research Alliance

Legal name

ATRX Research Alliance

Website

https://atrxresearch.org

Company type

Private

Founded year

2021

Operating status

Operating

Headcount range

1–10 employees

Short description

ATRX Research Alliance is a 501(c)(3) patient advocacy nonprofit founded in 2021 that supports families affected by ATR-X syndrome and funds translational research, operating a biobank, patient registry, drug repurposing, and gene therapy discovery programs for the global ATR-X community.

Ownership category

akta.pro rank

Product category

Rare Disease Patient Advocacy

akta.pro primary industry

Disease-Specific Research & Support (e.g., Cancer, Diabetes, ALS) (BPAGACAA)

Keywords

• Rare disease advocacy
• Patient registry services
• Biobanking biorepository
• Patient community support
• Rare disease research

Headquarters

HQ city

Albuquerque

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2C

Offering type

Services

Cost components

Personnel, Operations, Marketing or Sales, Others

Revenue model

1. Donations and Charitable Contributions: Tax-deductible donations through fiscal sponsor Rare Village Foundation, including online donations, check donations, wire transfers, and stock donations. Corporate matching supported.

Pricing tiers

Go-to-market motion1 record

Distribution channels2 records

Marketing channels8 records

Core offering

ATRX Research Alliance is a parent-led global nonprofit that accelerates ATR-X syndrome research through a patient registry (via Simons Searchlight), a biorepository of patient biospecimens and iPSC lines, drug repurposing and gene therapy discovery research collaborations, and an annual Scientific & Family Conference. It also operates a 900+ member global Facebook community with regional sub-groups to connect and support ATR-X patient families worldwide.

Product overview

ATRX Research Alliance is a non-profit patient advocacy organization (501c3) that operates as a single, unified offering—a global community dedicated to improving quality of life for ATR-X syndrome patients and accelerating research for treatments. The organization provides multiple interconnected services: a patient/family community platform (Facebook groups with 900+ members), biospecimen resources (biobank with iPSC lines, cell lines), patient registry (via Simons Searchlight partnership), drug repurposing research, and gene therapy discovery initiatives. The 2026 Scientific & Family Conference represents its flagship annual event combining family education with research collaboration opportunities.

Differentiator

Problem solved

Functional benefit

Products and services

• Patient Registry Captures de-identified data on ATR-X patients through the Simons Searchlight partnership, helping researchers and medical professionals provide quality healthcare, identify new symptoms, learn about the patient population, and provide data for therapeutic development. Families participate at no cost.
• Biobanking/Biorepository Biorepository of ATR-X syndrome biosamples banked and made available to interested researchers, with affected-patient families able to participate at no cost. Includes iPSC lines, cord blood, lymphoblastoid and fibroblast cell lines.
• Research Biospecimens Available biospecimens for approved research purposes, including 1 pair of iPSC lines (affected male; unaffected female control), 1 line of cord blood from affected male, plus lymphoblastoid and fibroblast cell lines banked through the partnership with Simons Searchlight.
• Scientific & Family Conference Annual conference bringing together families, researchers, clinicians, and partners from the global ATR-X community for connection, collaboration, and research advancement. Features sessions on understanding ATRX, research progress, therapeutic approaches, and family community building, with virtual attendance option.
• Facebook Community Groups Private Facebook community with over 900 members plus region-specific sub-groups (ATR-X American Families, ATRX UK, ATR-X Japan, ATR-X sindrome España/Latinoamerica) for peer support, resource sharing, and community connection among ATR-X patient families.
• Drug Repurposing Program Initiative to identify new therapeutic uses for existing drugs by growing a bank of patient-derived induced pluripotent stem cell (iPSC) lines representing commonly occurring genetic alterations, enabling research teams to study potential therapeutics in collaboration with Rarebase.
• Gene Therapy Discovery Research collaboration with Dr. David Picketts and Dr. Allison Bradbury to determine if ATR-X syndrome would benefit from gene therapy treatment, involving inoculation of a virus carrying a normal version of the ATRX gene.

Segments3 records

Ideal customer profiles3 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Integration3 records

Partnerships

17 partnerships are on record, tiered core and minor.

• Simons SearchlightcoreStrategic or Co-development PartnerARA has partnered with Simons Searchlight to create a biorepository for ATR-X syndrome. Biosamples from affected patients are banked and made available to interested researchers. Families can participate at no cost. ARA has also partnered with Simons Searchlight for patient registry initiatives.
• Greenwood Genetic CentercoreStrategic or Co-development PartnerResearch partnership with Greenwood Genetic Center, a premier genetics institution in South Carolina with medical genetics training programs, clinics, diagnostic laboratories, and research programs. Dr. Roger Stevenson serves on ARA's Scientific Advisory Board.
• Nationwide Children's Hospital (Bradbury Lab)coreStrategic or Co-development PartnerARA works with Dr. Allison Bradbury's lab at the Center for Gene Therapy, Abigail Wexner Research Institute. The Bradbury Lab focuses on developing therapeutic approaches for rare pediatric neurodegenerative disorders including ATR-X syndrome gene therapy.
• NIH (National Institutes of Health)coreStrategic or Co-development PartnerResearch partnership with National Institutes of Health supporting ARA's mission to advance rare disease research and therapeutic development.
• Ottawa Hospital Research Institute (Picketts Lab)coreStrategic or Co-development PartnerARA collaborates with Dr. David Picketts' laboratory at the Ottawa Hospital Research Institute. Dr. Picketts co-identified the ATRX gene and generates transgenic mouse models of ATR-X syndrome for research.
• University of Oxford (Gibbons Group)coreStrategic or Co-development PartnerARA collaborates with Dr. Richard Gibbons' group at Oxford's Weatherall Institute of Molecular Medicine. Dr. Gibbons leads the clinical and molecular diagnostic service for ATR-X syndrome with over 200 affected families and is on ARA's Scientific Advisory Board.
• Coriell InstituteminorStrategic or Co-development PartnerPartnership with Coriell for biospecimen banking and distribution to support ATR-X research initiatives.
• Rare Village FoundationcoreOthersATRX Research Alliance operates under fiscal sponsorship through Rare Village Foundation (EIN 83-4699994). All donations are tax-deductible through this fiscal sponsorship. ARA's EIN is 93-2674199.
• Harris-Martinez FamilyminorOthersFounding family and anchor donors who established ARA after their son Benjamin was diagnosed with ATR-X syndrome in 2019.
• Masri FamilyminorOthersAnchor donor family with son Ulises affected by ATR-X syndrome. Lautaro Masri and Sofia Ferrero actively support ARA initiatives from Argentina.
• Cure MitominorOthersAdvocacy partner organization for rare disease community collaboration and shared advocacy efforts.
• Cure VCP Disease IncminorOthersAdvocacy partner organization for rare disease community collaboration.
• KCNT1 EpilepsyminorOthersAdvocacy partner organization for rare disease community collaboration.
• KIF1A.orgminorOthersAdvocacy partner organization for rare disease community collaboration.
• SLC6A1 ConnectminorOthersAdvocacy partner organization for rare disease community collaboration.
• The40PercentminorOthersAdvocacy partner organization for rare disease community collaboration.
• Seizure Research Foundation (SRF)minorOthersAdvocacy partner organization for rare disease community collaboration.

Scale indicators3 records

Recent moves6 records

Expansion highlights5 records

Broad incumbents

• Global Genes: Rare disease advocacy umbrella organization providing toolkits, conferences (RARE Summit), and patient community resources to disease-specific groups like ARA. Comparable in mission scope but operates at the cross-disease level rather than disease-specifically.
• National Organization for Rare Disorders (NORD): Umbrella advocacy organization representing the broader rare disease community through policy, research grants, and patient assistance programs. ARA operates in the disease-specific niche within the rare disease ecosystem that NORD serves broadly.

Direct peers

• International Rett Syndrome Foundation: Rett syndrome patient advocacy and research-funding nonprofit operating a patient registry, biobank, and research conference infrastructure. Closely comparable to ARA in targeting an X-linked neurodevelopmental disorder with limited treatment options.
• Cure SMA: Spinal muscular atrophy patient advocacy organization that historically funded basic research and helped drive development of the first disease-modifying treatments (Spinraza, Zolgensma). Closest analog to ARA in terms of patient-led rare disease research acceleration playbook.
• Children's Tumor Foundation: Neurofibromatosis patient advocacy organization funding NF research, running patient registries, and hosting research conferences. Comparable to ARA in disease-specific rare disease research acceleration with multi-institutional academic partnerships.
• COMBINEDBrain: Consortium of rare neurodevelopmental disorder patient organizations pooling resources to accelerate drug development across diseases too small to attract industry investment individually. ARA could plausibly join as a participant for ATR-X syndrome.
• Parent Project Muscular Dystrophy: Parent-led nonprofit accelerating Duchenne muscular dystrophy research through patient registries, biobanking, and research funding. Highly comparable operating model to ARA — small staff, family-driven, research-grant-making, SAB-driven — applied to a different rare genetic disease.
• National Ataxia Foundation: Ataxia patient advocacy organization supporting research into rare hereditary ataxias through grants, registries, and annual scientific conferences. Direct operational analog to ARA for a related neurodevelopmental/movement disorder space.
• Cure Rare Disease: Nonprofit developing gene therapies for ultra-rare diseases using patient-led research funding models. Shares ARA's gene therapy discovery orientation and commitment to individualized therapeutic development for diseases too rare for commercial focus.
• Foundation for Prader-Willi Research: Parent-driven nonprofit funding Prader-Willi syndrome research through grants, patient registries, and conferences. Mirrors ARA's combination of family community, research grantmaking, and scientific convening for an ultra-rare neurodevelopmental disorder.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

• Facebookfacebook.com/ATRXResearchAlliance
• LinkedInlinkedin.com/company/atrxresearch
• Instagraminstagram.com/atrxresearchalliance

Compliance1 record

Revenue estimate

Valuation estimate

Number of profiles

Profiles2 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about ATRX Research Alliance